These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 17361493)

  • 21. Drug for severe sepsis is withdrawn from market, fails to reduce mortality.
    Mitka M
    JAMA; 2011 Dec; 306(22):2439-40. PubMed ID: 22166598
    [No Abstract]   [Full Text] [Related]  

  • 22. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Girbes AR; Polderman KH; Beishuizen A; van Zanten AR; Schultz MJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1265-6; author reply 1266. PubMed ID: 16796179
    [No Abstract]   [Full Text] [Related]  

  • 23. New mode of intervention in sepsis treatment.
    Foubister V
    Drug Discov Today; 2003 Jul; 8(14):610-2. PubMed ID: 12867140
    [No Abstract]   [Full Text] [Related]  

  • 24. Targeting the coagulation cascade in sepsis: did we find the "magic bullet"?
    Mathiak G; Neville LF; Grass G
    Crit Care Med; 2003 Jan; 31(1):310-1. PubMed ID: 12545036
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of sepsis therapies on health-related quality of life.
    Erickson SE; Martin GS
    Crit Care; 2008; 12(1):109. PubMed ID: 18254930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Sepsis in the surgical setting: indication for activated C protein].
    Payen DM; Matéo J
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():40-2. PubMed ID: 15359942
    [No Abstract]   [Full Text] [Related]  

  • 27. Management of sepsis.
    Khurana A; Vinayek N
    N Engl J Med; 2007 Mar; 356(11):1178-9; author reply 1181-2. PubMed ID: 17366659
    [No Abstract]   [Full Text] [Related]  

  • 28. A blind clinical evaluation committee should, in theory, make data of a randomized clinical trial stronger, not weaker.
    Carlet J
    Intensive Care Med; 2004 May; 30(5):994; author reply 995. PubMed ID: 15083270
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment of severe sepsis and multiple organ failure with activated protein C].
    Strøm JJ
    Ugeskr Laeger; 2004 Mar; 166(11):995. PubMed ID: 15049233
    [No Abstract]   [Full Text] [Related]  

  • 30. Applying patient selection criteria for drotrecogin alfa therapy in practice.
    Wong-Beringer A; Liao C; Nguyen M; Pallares J
    Am J Health Syst Pharm; 2003 Jul; 60(13):1345-52. PubMed ID: 12901037
    [No Abstract]   [Full Text] [Related]  

  • 31. Drotrecogin alfa: excess mortality in the least severely ill patients.
    Prescrire Int; 2005 Aug; 14(78):145. PubMed ID: 16108104
    [No Abstract]   [Full Text] [Related]  

  • 32. [Clinical experience with xigris].
    Wyncoll D
    Ann Fr Anesth Reanim; 2003 Dec; 22 Spec No 1():46-7. PubMed ID: 15359944
    [No Abstract]   [Full Text] [Related]  

  • 33. Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated).
    Critical Care Society of South Africa Working Group
    S Afr Med J; 2003 Jun; 93(6):416-7. PubMed ID: 12916374
    [No Abstract]   [Full Text] [Related]  

  • 34. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    McEvoy M
    Am J Crit Care; 2003 Sep; 12(5):398; author reply 398. PubMed ID: 14503421
    [No Abstract]   [Full Text] [Related]  

  • 35. A new weapon against severe sepsis related to necrotizing fasciitis.
    Purnell D; Hazlett T; Alexander SL
    Dimens Crit Care Nurs; 2004; 23(1):18-23. PubMed ID: 14734896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    Morris PE
    Am J Crit Care; 2003 Mar; 12(2):94-7. PubMed ID: 12625165
    [No Abstract]   [Full Text] [Related]  

  • 37. The Sepsis Saga: Consensus to Xigris.
    Dries DJ
    Air Med J; 2016; 35(4):194-6. PubMed ID: 27393750
    [No Abstract]   [Full Text] [Related]  

  • 38. What is the role of recombinant activated protein C in the management of sepsis?
    Alvarado J; Castro R
    Medwave; 2016 Dec; 16(Suppl5):e6801. PubMed ID: 28032853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combating mortality from severe sepsis.
    Ridley S
    Hosp Med; 2004 Oct; 65(10):580-1. PubMed ID: 15524335
    [No Abstract]   [Full Text] [Related]  

  • 40. Activated protein C: beyond 28 days.
    Manocha S; Walley KR
    Crit Care Med; 2004 Nov; 32(11):2348-9. PubMed ID: 15640656
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.